Shopping Cart
- Remove All
![TargetMol](https://newstatic.targetmol.com/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 mg | $41 | In Stock |
Description | L-DABA hydrobromide (L-2,4-Diaminobutyric acid hydrobromide) is a potent GABA transaminase inhibitor with antitumor and anticonvulsant activity for the study of neurological disorders. |
In vitro | Incubation with 10 mM L-2,4-Diaminobutyric acid for 24 h at 37°C irreversibly and completely damages tumor cells. The cell-destructive effect caused by L-DABA hydrobromide is likely a result of osmotic lysis induced by the non-saturated intracellular accumulation of L-DABA hydrobromide. Concomitant incubation with L-alanine and L-methionine can abolish the harmful effect of L-DABA hydrobromide[1]. Kinetic studies indicate that L-DABA hydrobromide is a non-linear, non-competitive inhibitor of GABA transaminase activity. The elevation of GABA levels induced by L-DABA hydrobromide parallels the inhibition of GABA transaminase activity[2]. L-2,4-Diaminobutyric acid, an amino acid analogue, produces a cytolytic effect with a human glioma cell line, SKMG-1, and normal human fibroblasts. The concentrations of L-DABA hydrobromide necessary to reduce the cell count to 50% of control following a 24-h incubation at 37°C are 12.5 mM for the human fibroblasts and 20 mM for the glioma cell line[2]. |
In vivo | Treatment with L-DABA hydrobromide results in a 43.4% reduction of tumor growth[1]. In vivo, L-DABA hydrobromide is a more effective inhibitor of GABA transaminase compared to its efficacy in vitro[3]. |
Alias | L-2,4-Diaminobutyric acid hydrobromide |
Molecular Weight | 199.05 |
Formula | C4H11BrN2O2 |
Cas No. | 73143-97-2 |
Storage | keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year | |||||||||||||||
Solubility Information | DMSO: 1.99 mg/mL (10 mM) ![]() | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.